Conditions: Esophageal Adenocarcinoma Gastric Adenocarcinoma
Keywords: gastric esophageal panitumumab
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 17
Healthy volunteers: no

Brief summary:
A pilot study to determine the safety of using perioperative panitumumab with EOX (epirubicin, oxaliplatin, and capecitabine) in patients with adenocarcinoma of the esophagus and stomach.

Detailed description:

Arms:
arm 1: open-label, single-arm EOXP Epirubicin 50mg/m2 by IV on day 1 of each 21 day cycle, Oxaliplatin 100 mg/m2 by IV on day 1 of each 21 day cycle, Capecitabine 400 mg/m2 twice daily by mouth on days 1-21 of the 21 day cycle Panitumumab - 9mg/kg by IV on day 1 of each 21 day cycle

Interventions: intervention 1: panitumumab, epirubicin, oxaliplatin, xeloda
Intervention descriptions: intervention 1: pilot study

Protocol document: